Special Issue
Clinical antibody drug conjugates
Submission Deadline: 31 December 2014
Articles: 3
Special Issue Editor
Guest Editor
Arthur E. Frankel
Professor of Medicin, Scott and White Hospital, 2401 South 31st Street, Temple, Texas 76508
Expertise: 215 publications, 20 grants, Editor of Frontiers in Bioscience, Molecular Cancer Therapeutics, Clinical Cancer Research, Clinical Pharmacology:Advances and Applications
Manuscript Submission Information

Manuscripts should be submitted online at https://jour.ipublishment.com/bri by registering and logging into this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page.

Please visit the Instructions for Authors page before submitting a manuscript. Submitted papers should be well formatted and written in clear, concise English and should contain all essential data in order to make the presentation clear and the results of the study replicable. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see


Cancer, Therapeutics
Share This Special Issue
Published Papers (3 papers)
Open Access
Antibody-drug conjugates targeting prostate-specific membrane antigen
William C. Olson, Robert J. Israel
Frontiers in Bioscience-Landmark Volume 19 Issue 1, pp.12-33
Managing Editor: Arthur E. Frankel
DOI: 10.2741/4193 Published: 01 January 2014
Open Access

Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma

Jesus G. Berdeja
Frontiers in Bioscience-Landmark Volume 19 Issue 1, pp.163-170
Managing Editor: Arthur E. Frankel
DOI: 10.2741/4202 Published: 01 January 2014
Open Access

Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin

Andrew J. Cowan, George S. Laszlo, Elihu H. Estey, Roland B. Walter
Frontiers in Bioscience-Landmark Volume 18 Issue 4, pp.1311-1334
Managing Editor: Arthur E. Frankel
DOI: 10.2741/4181 Published: 01 June 2013